Hospital

STRIDE regimen of a single priming dose added to Imfinzi is the first dual immune checkpoint blockage regimen to improve overall survival in a phase 3 trial in this setting.

The PREVENT-19 study evaluates the immunogenicity and safety of a third dose of NVX-CoV2373 in children aged 12 to 17 years.

Intra Cellular Therapies’ Lumateperone is available in the 10.5- and 21-mg strengths and can also be used to treat depressive episodes associated with bipolar I or II disorder.

Belumosudil is indicated to treat individuals aged 12 years and older with chronic graft-versus-host disease who have received at least 2 prior systemic therapy treatments without success.

Students and new graduates can excel in their career through leadership, communication skills, and self-efficacy.

An expert panel engaged the audience in a live virtual symposium and case discussion on immune checkpoint inhibitors (ICIs) in the first-line treatment of non−small cell lung cancer (NSCLC) at the 2021 ASHP Midyear Clinical Meeting.

An engineered live biotherapeutic product may help limit antibiotic resistance versus pathogens such as Clostridioides difficile.

COVID-19 is associated with longer stays in the intensive care unit, which costs nearly twice as much to treat.

Tamsulosin (Flomax) is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia.

Because of the likelihood that patients with melanoma will develop adverse effects on therapy, it is crucial for pharmacists to proactively educate patients and provide them with tools to help mitigate and manage these issues.

In a case study, the symptoms associated with the rash are fatigue, migratory lower extremity joint pain, and swelling of the ankles and feet.

ARCT-154 demonstrates 95% efficacy overall for prevention of severe disease, including related deaths.

As pharmacy technicians continue to take on more responsibilities, actions must be taken to alleviate the burnout so many are facing.

Attendees of this live virtual program learned the latest and greatest in a presentation from 2 expert oncology pharmacists.

Depression can make people who have recovered from COVID-19 feel less enthusiastic in their daily lifestyle.

Conditions such as high blood pressure, diabetes, and obesity may have a significant impact on the likelihood of developing cognitive decline, dementia, and Alzheimer disease.

Letermovir has been approved by the FDA to prevent severe CMV in patients who are asymptomatic and undergoing allogeneic hematopoietic stem cell transplants.

FDA-approved Disulfiram can safely reduce anxiety levels in rodents, analysis from the Tokyo University of Sciences and other Japan institutes finds.

The first cases were identified in October 2021 at a children’s hospital in Alabama that admitted 5 children with significant liver injury, including some with acute liver failure.

The booster vaccine candidate includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants such as the Omicron variant.

The results lead to a possible new therapeutic approach to improve immunotherapy outcomes, including combinations with vitamin E, as well as directly targeting SHP1 in dendritic cells.

DuoBody, for treatment of relapsed/refractory large B-cell lymphoma, demonstrates an overall response rate of 63.1%.

New analysis demonstrates that physical activity improves cognitive health, thus staving off dementia.

In a live virtual symposium at the 2021 ASHP Midyear Clinical Meeting, 2 experts teamed up to highlight the place in therapy and management of oral oncolytics in follicular and marginal zone lymphoma.

32 public colleges with combined enrollment of more than 700,000 students must comply with law by January 2023.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, offers guidance for female medical researchers who are faced with a declining number of female colleagues in the workforce.

The CIC is a combination of Novavax’s COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate.

The application is based on positive results from the ASCEND phase 3 clinical trial, assessing the efficacy and safety of daprodustat for the treatment of anemia from chronic kidney disease.